As women ourselves, we understood how personal that standard needed to be. For decades, women’s intimate health has been treated as an afterthought — over-medicated, under-researched, and rarely designed with long-term biology in mind.
Data shows that over 60% of women will experience a urinary tract infection in their lifetime, and up to half of those will experience recurrence.
Vaginal atrophy and microbiome disruption affect millions more, particularly during menopause — yet for women who cannot or choose not to use hormones, well-designed therapeutic alternatives remain limited. As a result, many women are left with a difficult reality:
Hormones are often the first-line solution. Antibiotics are frequently overused. Short-term relief is treated as enough.
So, we decided to change the standard.
Instead of masking symptoms, introducing harsh acids, or overlooking women seeking effective hormone-free care, Dr. Janet Akande-Dokun, an expert in advanced drug delivery and formulation design, and Dr. Ore Adedoyin, a leader in drug product research and development, recognized a scientific gap — a lack of rigorously designed and safely delivered therapies built to support complex biological tissues.
Drawing on more than 50 years of combined pharmaceutical science experience, they now lead a multidisciplinary team that brings together pharmaceutical science and clinical expertise.
Working closely with gynecologists, they translate real-world patient insight directly into product design and formulation.
Each Moremmé product is designed to support the vaginal microbiome’s natural balance, restoring tissue health, and easing discomfort. No hormones. No gimmicks. No compromises.